Citadel Securities Upgrades Questcor Pharmaceuticals (QCOR) to Edge Positive; Strong Outlook Into Nephrotic Syndrome Expansion

Citadel Securities upgraded Questcor Pharmaceuticals (NASDAQ: QCOR) from Neutral to Edge Positive, price target raised from $23 to $44.

Citadel analyst says, "We are upgrading QCOR shares based on our high conviction for strong Acthar revenues in Nephrotic Syndrome and continued growth in Multiple Sclerosis Flares. Our $44 price target is based on an increase in our peak sales estimate for Acthar in Nephrotic Syndrome to $140MM from $50MM, resulting in a total value of $44 per share based on a P/E sensitivity analysis on a per indication basis."

For more ratings news on Questcor Pharmaceuticals click here and for the rating history of Questcor Pharmaceuticals click here.

Shares of Questcor Pharmaceuticals closed at $28.65 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA Securities Upgrades Moderna (MRNA) to Neutral
• Citi Upgrades JSL SA (JSLG3:BZ) to Buy
• Citi Upgrades Toyoda Gosei Co Ltd (7282:JP) to Buy